SCHEMBL2644101

SCHEMBL2644101

CC1(C)Cc2c(Oc3ccc(C(=O)N4CC(F)(F)C4)cc3)cc(C(=O)O)cc2O1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 2/20 0.45
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
RXRA P19793 2/20 0.37
FFAR4 Q5NUL3 2/20 0.36
ALDH1A1 P00352 6/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
TSHR P16473 1/20 0.35
HPGD P15428 4/20 0.35
KDM4E B2RXH2 3/20 0.35
GLA P06280 3/20 0.35
GAA P10253 3/20 0.35
CASP1 P29466 1/20 0.35
CASP7 P55210 1/20 0.35
HSD17B10 Q99714 1/20 0.35
RXRB P28702 1/20 0.34
RXRG P48443 1/20 0.34
NQO2 P16083 1/20 0.33
PTGER2 P43116 1/20 0.33
PDE3B Q13370 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15780515 0.92 GCK (0.45) GCKMEN1KMT2AFFAR4ALDH1A1
SCHEMBL2643898 0.88 GCK (0.52) GCKMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL643904 0.88 GCK (0.54) GCKMEN1KMT2ARXRAALDH1A1
SCHEMBL2645813 0.88 GCK (0.59) GCKFFAR4ALDH1A1KDM4EHSD17B10
SCHEMBL2644398 0.87 GCK (0.42) GCKMEN1KMT2AFFAR4
SCHEMBL2644795 0.86 GCK (0.47) GCKKMT2AALDH1A1L3MBTL1TSHR
SCHEMBL2644490 0.83 KMT2A (0.44) GCKMEN1KMT2ARXRAFFAR4
SCHEMBL9071962 0.82 GCK (0.43) GCKMEN1KMT2A
SCHEMBL643672 0.82 GCK (0.70) GCKNPC1KCNH2
SCHEMBL642785 0.80 ALDH1A1 (0.46) GCKRXRAFFAR4ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2463283-B1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases PFIZER PROD INC (US) 2014-06-11 EP disclosed
EP-2010520-B1 HETEROBICYCLIC AMIDES FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES PFIZER PROD INC (US) 2012-09-12 EP disclosed
EP-2463283-A1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases Pfizer Products Inc. (US) 2012-06-13 EP disclosed
US-7842713-B2 Fused phenyl amido heterocyclic compounds PFIZER INC (US) 2010-11-30 US disclosed
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS PFIZER INC. 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS GCK, GCKR, HK1 GCK 1/4885MEN1 2702/4885KMT2A 1755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.